Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine and Cisplatin in UTUC
NCT01663285Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2012
- Primary completion
- Jan 2014
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and Cisplatin micelle injection (HA132) in upper tract urothelial carcinoma (UTUC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Recurrence-free Survival Time at 2 years. Started Sep 2012; status: terminated.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT01663285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663285.